A new report by visiongain predicts that revenues for disease-modifying treatments for multiple sclerosis (MS) will rise to $15.8bn annually in 2015. That analysis appears in Multiple Sclerosis Treatment: World Drug Market 2012-2022.
Visiongain predicts that world revenues for rheumatoid arthritis drugs will rise strongly between 2011 and 2021. This market will grow to reach $17.3bn in 2015. The rheumatoid arthritis drugs market generated $12.7bn in 2010.
A new report by visiongain predicts that the global companion diagnostics market will be worth $3.45bn by 2015. The market generated sales of $1.30bn in 2010, according to Companion Diagnostics: World Market Outlook 2011-2021, published in August.